Prevention and Treatment of Candida Infections in Neonates

Seminars in Perinatology

Volumn 31, Issue 1, 2007, Pages 39-46

  Chapman, Rachel L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antifungal chemotherapy; antifungal prophylaxis; Candida; fungemia; late onset sepsis; very low birthweight infant

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CEPHALOSPORIN DERIVATIVE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; LIPID EMULSION; MICONAZOLE; NYSTATIN; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ABDOMINAL SURGERY; ANTIBIOTIC THERAPY; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDIASIS; CENTRAL VENOUS CATHETER; DRUG EXPOSURE; FUNGAL STRAIN; HUMAN; INFECTION PREVENTION; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; PARENTERAL NUTRITION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VERY LOW BIRTH WEIGHT;

ANTIFUNGAL AGENTS; CANDIDIASIS; DRUG THERAPY, COMBINATION; HUMANS; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT;

EID: 33847018099     PISSN: 01460005     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semperi.2007.01.006     Document Type: Review

References (97)

1. Stoll B.J., Hansen N., Fanaroff A.A., et al. Late-onset sepsis in very low birth weight neonates: the experience of the National Institute of Child Health and Human Development Neonatal Research Network. Pediatrics 110 (2002) 285-291
2. Kosoff E.H., Bueshcer E.S., and Karlowicz M.G. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 17 (1998) 504-508
3. Beck-Sague C., Jarvis W.R., and National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 167 (1993) 1247-1251
4. Makhoul I.R., Kassis I., Smolin T., et al. Review of 49 neonates with acquired fungal sepsis: further characterization. Pediatrics 107 (2001) 61-66
5. Saiman L., Ludington E., Pfaller M., et al. Risk factors for candidemia in neonatal intensive care unit patients. Pediatr Infect Dis J 19 (2000) 319-324
6. Faix R.G., Kovarik S.M., Shaw T.R., et al. Mucocutaneous and invasive candidiasis among very low birth weight infants in intensive care nurseries: a prospective study. Pediatrics 83 (1989) 101-107
7. Bayley J.E., Kliegman R.M., and Fanaroff A.A. Disseminated fungal infections in very low birth weight infants: clinical manifestations and epidemiology. Pediatrics 73 (1984) 144-152
8. Huang Y.-C., Lin T.-Y., Leu H.-S., et al. Outbreak of Candida parapsilosis fungemia in neonatal intensive care units: clinical implications and genotyping analysis. Infection 27 (1999) 97-102
9. Kaufman D., Boyle R., Hazen K.C., et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 345 (2001) 1660-1666
10. Manzoni P., Arisio R., Mostert M., et al. Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year retrospective cohort study. Pediatrics 117 (2006) e22-e32
11. Bertini G., Perugi S., Dani C., et al. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr 147 (2005) 162-165
12. Uko S., Soghier L.M., Vega M., et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics 117 (2006) 1243-1252
13. Healy C.M., Baker C.J., and Zaccaria B.S. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr 147 (2005) 166-171
14. Bayley J.E., Rivers A., Clapp D.W., et al. Two year outcome of systemic candidiasis in VLBW infants. Pediatr Res 23 (1988) 441A
15. Friedman S., Richardson S.E., Jacobs S.E., et al. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 19 (2000) 499-505
16. Benjamin Jr. D.K., Stoll B.J., Fanaroff A.A., et al. Neonatal candidiasis among infants <1000g birthweight: risk factors, mortality, and neurodevelopmental outcomes at 18-22 months. Pediatrics 117 (2006) 84-92
17. Benjamin Jr. D.K., Poole C.W., Steinbach W.J., et al. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 112 (2003) 634-640
18. Chapman R.L., and Faix R.G. Persistently positive cultures and outcome in invasive neonatal candidiasis. Pediatr Infect Dis 19 (2000) 822-827
19. Noyola D.E., Fernandez M., Moylett E.H., et al. Opthamologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis 32 (2001) 1018-1023
20. Faix R.G. Invasive neonatal candidiasis: comparison of albicans and parapsilosis infection. Pediatr Infect Dis J 11 (1992) 88-93
21. Trick W.E., Fridkin S.K., Edwards J.R., et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 35 (2002) 627-630
22. Kao A.S., Brandt M.E., Pruitt W.R., et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 29 (1999) 1164-1170
23. Fairchild K.D., Smita T., Sharp E., et al. Neonatal Candida glabrata sepsis: clinical and laboratory features compared with other Candida species. Pediatr Infect Dis J 21 (2002) 39-43
24. Abi-Said D., Anaissie E., Uzun O., et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24 (1997) 1122-1128
25. Waggoner-Fountain L.A., Whit Walker M., Hollis R.J., et al. Vertical and horizontal transmission of unique Candida species to premature newborns. Clin Infect Dis 22 (1996) 803-808
26. Reef S.E., Lasker B.A., Butcher D.A., et al. Nonperinatal nosocomial transmission of Candida albicans in a neonatal intensive care unit: prospective study. J Clin Microbiol 36 (1998) 1255-1259
27. Vazquez J.A., Boikov D., Boikov S.G., et al. Use of electrophoretic karyotyping in the evaluation of Candida infections in a neonatal intensive-care unit. Infect Control Hosp Epidemiol 18 (1997) 32-37
28. Saiman L., Ludington E., Dawson J.D., et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 20 (2001) 1119-1124
29. Bayley J.E., Kliegman R.M., Boxerbaum B., et al. Fungal colonization in the very low birth weight infant. Pediatrics 78 (1986) 225-232
30. Kaufman D.A., Gurka M.J., Hazen K.C., et al. Patterns of fungal colonization in preterm infants weighing less than 1000 grams at birth. Pediatr Infect Dis J 25 (2006) 733-737
31. Weese-Mayer D.E., Fondriest D.W., Brouillette R.T., et al. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatr Infect Dis J 6 (1987) 190-196
32. Cotton C.M., McDonald S., Stoll B., et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 118 (2006) 717-722
33. Benjamin Jr. D.K., Ross K., and McKinney Jr. R.E. When to suspect fungal infection in neonates: a clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. Pediatrics 106 (2000) 712-718
34. Botas C.M., Kurlat I., Young S.M., et al. Disseminated candidal infections and intravenous hydrocortisone in preterm infants. Pediatrics 95 (1995) 883-887
35. Pera A., Byun A., Gribar S., et al. Dexamethasone therapy and Candida sepsis in neonates less than 1250 grams. J Perinatol 22 (2002) 204-208
36. Walsh T.J., and Hutchins G.M. Postoperative Candida infections of the heart in children: clinicopathologic study of a continuing problem of diagnosis and therapy. J Pediatr Surg 15 (1980) 325-331
37. Campbell J.R., Zaccaria E., and Baker C.J. Systemic candidiasis in extremely low birth weight infants receiving topical petrolatum ointment for skin care: a case-control study. Pediatrics 105 (2000) 1041-1045
38. Rowen J.L., Atkins J.T., Levy M.L., et al. Invasive fungal dermatitis in the ≤1000-gram neonate. Pediatrics 95 (1995) 682-687
39. Rabalais G.P., Samiec T.D., Bryant K.K., et al. Invasive candidiasis in infants weighing more than 2500 grams at birth admitted to a neonatal intensive care unit. Pediatr Infect Dis J 15 (1996) 348-352
40. Shetty S.S., Harrison L.H., Hajjeh R.A., et al. Determining risk factors for candidemia among newborn infants from population-based surveillance: Baltimore, Maryland, 1998-2000. Pediatr Infect Dis J 24 (2005) 601-604
41. Pizzo P.A., Robichaud K.J., Gill F.A., et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72 (1982) 101-110
42. Ellepola A.N., and Morrison C.J. Laboratory diagnosis of invasive candidiasis. J Microbiol 43 (2005) 65-84
43. Rex J.H., Walsh T.J., Sobel J.D., et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 30 (2000) 662-678
44. Eppes S.C., Troutman J.L., and Gutman L.T. Outcome of treatment of candidemia in children whose central catheters were removed or retained. Pediatr Infect Dis J 8 (1989) 99-104
45. Bayley J.E., Meyers C., Kliegman R.M., et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 116 (1990) 791-797
46. Starke J.R., Mason Jr. E.O., Kramer W.G., et al. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis 155 (1995) 766-774
47. Kingo A.R., Smyth J.A., and Waisman D. Lack of evidence of amphotericin B toxicity in very low birth weight infants treated for systemic candidiasis. Pediatr Infect Dis J 16 (1997) 1002-1003
48. Butler K.M., Rench M.A., and Baker C.J. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 9 (1990) 51-56
49. Rowen J.L., Tate J.M., and Neonatal Candidasis Study Group. Management of neonatal candidiasis. Pedatr Infect Dis J 17 (1998) 1007-1011
50. Benjamin Jr. D.K., and Benjamin D.K. Candidal mycetoma in the neonatal kidney. Pediatrics 104 (1999) 1126-1129
51. Berman L.H., Stringer D.A., St. Onge A.D., et al. An assessment of sonography in the diagnosis and management of neonatal renal candidiasis. Clin Radiol 40 (1989) 577-581
52. Adler-Shohet F., Waskin H., and Lieberman J.M. Amphotericin B lipid complex for neonatal invasive candidiasis. Arch Dis Child Fetal Neonatal Ed 84 (2001) F131-F133
53. Scarcella A., Pasquariello M.B., Giugliano B., et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infec Dis J 17 (1998) 146-148
54. Walsh T.J., Seibel N.L., Arndt C., et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 18 (1999) 702-708
55. Weitkamp J.H., Poets C.F., Sievers R., et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection 26 (1998) 11-15
56. Juster-Reicher A., Leibovitz E., Linder N., et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 28 (2000) 223-226
57. Linder N., Klinger G., Shalit I., et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother 51 (2003) 513-521
58. McClenny N.B., Fei H.H., Baron E.J., et al. Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance. Antimicrob Agents Chemother 46 (2002) 1325-1328
59. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47 (2003) 3149-3154
60. Pfaller M.A., Diekema D.J., Jones R.N., et al. Trends in antifungal susceptibility of Candida spp. Isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997 to 2000. J Clin Microbiol 40 (2002) 852-856
61. Messer S.A., Jones R.N., and Fritsche T.R. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program. (2003). J Clin Microbiol 44 (2006) 1782-1787
62. Francis P., and Walsh T.J. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 15 (1992) 1003-1018
63. Baley J.E., Meyers C., Kliegman R.M., et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 116 (1990) 791-797
64. Butler K.M., Rench M.A., and Baker C.J. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 9 (1990) 51-56
65. Huttova M., Hartmanova I., Kralinsky K., et al. Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. Pediatr Infect Dis J 17 (1998) 1012-1015
66. Fasano C., O'Keeffe J., and Gibbs D. Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. Eur J Clin Microbiol Infect Dis 13 (1994) 351-354
67. Huang Y.-C., Lin T.-Y., Lien R.-I., et al. Fluconazole therapy in neonatal candidemia. Am J Perinatol 17 (2000) 411-415
68. Bilgen H., Özek E., Korten V., et al. Treatment of systemic neonatal candidiasis with fluconazole. Infection 23 (1995) 394
69. Wainer S., Cooper P.A., Gouws H., et al. Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatr Infect Dis J 16 (1997) 763-767
70. Driessen M., Ellis J.B., Cooper P.A., et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 15 (1996) 1107-1112
71. Brammer K.W., and Coates P.E. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis 13 (1994) 325-329
72. Wenzl T.G., Schefels J., Hörnchen H., et al. Pharmacokinetics of oral fluconazole in premature infants. Eur J Pediatr 157 (1998) 661-662
73. Rowen J.L., Tate J.M., Nordoff N., et al. Candida isolates from neonates: frequency of misidentification and reduced fluconazole susceptibility. J Clin Microbiol 37 (1999) 3735-3737
74. Nguyen M.H., Peacock J.E., Morris A.J., et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100 (1996) 617-623
75. Sarvikivi E., Lyytikäinen O., Soll D.R., et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 43 (2005) 2729-2735
76. Walsh T.J., Karlsson M.O., Driscoll T., et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agent Chemother 48 (2004) 2166-2172
77. Walsh T.J., Lutsar I., Driscoll T., et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21 (2002) 240-248
78. Muldrew K.M., Maples H.D., Stowe C.D., et al. Intravenous voriconazole therapy in a preterm infant. Pharmacotherapy 25 (2005) 893-898
79. Pfaller M.A., Diekema D.J., Messer S.A., et al. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 47 (2003) 1068-1071
80. Odio C.M., Araya R., Pinto L.E., et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 23 (2004) 1093-1097
81. Belet N., Ciftci E., Ince E., et al. Caspofungin treatement in two infants with persistent fungaemia due to Candida lipolytica. Scand J Infect Dis 38 (2006) 559-562
82. Yalaz M., Akisu M., and Hilmiogul S. Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicaemia in an extremely low birth weight neonate. Mycoses 49 (2006) 242-245
83. Manzar S., Kamat M., and Pyati S. Caspofungin for refractory candidemia in neonates. Pediatr Infect Dis J 25 (2006) 282-283
84. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbio Infect Dis 24 (2005) 654-661
85. Johnson M.D., MacDougall C., Ostosky-Zeichner L., et al. Combination antifungal therapy. Antimicrob Agents Chemother 48 (2004) 693-715
86. Patterson T.F. Combination antifungal therapy. Pediatr Infect Dis J 22 (2003) 553-556
87. Sobel J.D. Combination therapy for invasive mycoses: evaluation of past clinical trail designs. Clin Infect Dis 39 (2004) S224-S227
88. Rex J.H., Pappas P.G., Karchmer A.W., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo vs. fluconazole plus amphotericin B as therapy of candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36 (2003) 1221-1228
89. Roling E.E., Klepser M.E., Wasson A., et al. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. And Cryptococcus neoformans via time-kill methods. Diagn Microbiol 43 (2002) 13-17
90. Graybill J.R., Bocanegra L.K., Najvar S., et al. Addition of capsofungin to fluconazole does not improve outcome in murine candidiasis. Antimicrob Agents Chemother 47 (2003) 2373-2375
91. Sims M.E., Yun Y., You H., et al. Prophylactic oral nystatin and fungal infections in very-low-birthweight infants. Am J Perinatol 5 (1988) 33-36
92. Wainer S., Cooper P.A., Funk E., et al. Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection. Pediatr Infect Dis J 11 (1992) 713-716
93. Kicklighter S.D., Springer S.C., Cox T., et al. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 107 (2001) 293-298
94. Kaufman D., Boyle R., Hazen K.C., et al. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr 147 (2005) 172-179
95. McGuire W., Clerihew L., and Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database System Rev 1 (2004) CD003850
96. Cabrera C., Frank M., Carter D., et al. Fluconazole prophylaxis against systemic candidiasis after colonization: a randomized, double-blinded study. J Perinatol 22 (2002) 604
97. Long S.L., and Stevenson D.K. Reducing Candida infections during neonatal intensive care: management choices, infection control, and fluconazole prophylaxis. J Pediatr 147 (2005) 135-141